The Trump administration has announced a series of measures including a significant 100% tariff on select pharmaceutical imports. This action targets companies that have not lowered their drug prices, with various exemptions for some manufacturers. The new tariffs coincide with adjustments to existing metal tariffs, signaling a strong push for U.S. manufacturing and supply chain security. President Trump emphasized the urgency for drugmakers to strike agreements to reduce prices or face steep penalties. The measures have raised concerns in pharmaceutical stocks and are expected to impact trade dynamics significantly.